In many tumour cell lines with acquired MDR, drug resistance is associated with the overexpression of a plasma membrane protein, P-glycoprotein (Pgp), the product of the mdrl gene (Endicott & Ling, 1989) . Pgp functions as an energydependent drug efflux pump, which decreases free cellular drug concentrations, thus rendering cells resistant to cytotoxic agents . However, in some cancers, such as lung and breast, the expression of Pgp in general is low and/or heterogeneous (Lai et al., 1989; Linn et al., 1992) , implicating that other resistance mechanisms contribute to clinical resistance.
A number of drug-selected cell lines has now been reported to show the MDR phenotype (resistance to a wide range of cytostatic agents with no common structure or target) but without the overexpression of Pgp (so called non-Pgp MDR) (McGrath et al., 1989 Coley et al., 1991; Slovak et al., 1988; Ta.ylor et al., 1991) . In some of these non-Pgp MDR cell lines the expression of mdrl is even decreased (Baas et al., 1990) . Thus far at least two mechanisms have been shown to be operative in drug resistance in non-Pgp MDR cells. The first mechanism is a decreased drug concentration at target due to a decreased cellular accumulation of drugs (McGrath et al., 1989; Kuiper et al., 1990; Coley et al., 1991; Slovak et al., 1988; Taylor et al., 1991) and/or an altered distribution of drugs (Schuurhuis et al., 1991; Takeda et al., 1991) . We have previously shown by using a digitonin based assay that the decrease in DNR accumulation occurred against a concentration gradient in a number of Pgp and non-Pgp MDR cell lines (Versantvoort et al., 1992a) . Furthermore in some non-Pgp MDR cell lines the accumulation of drugs was shown to be decreased due to an energy-dependent mechanism (Coley et al., 1991; Marquardt et al., 1990; Versantvoort et al., 1992b) . Therefore other drug transporters than Pgp have to be present in those non-Pgp MDR cells. The second mechanism that contributes to the resistance in several non-Pgp MDR cells is an alteration in topoisomerase II activity (Slovak et al., 1988; De Jong et al., 1990) .
In non-Pgp MDR cells the effects of Pgp resistance modifiers such as verapamil and chloroquine usually are less than in Pgp MDR cells (Schuurhuis et al., 1991; Cole et al., 1989; Zijlstra et al., 1987) . It is therefore of interest to search for resistance modulators more effective and selective for non-Pgp MDR, in order to be able to modulate non-Pgp mediated MDR and to gain more insight into the properties of the drug transporter(s) involved.
Recently, several reports have indicated that modulators of protein kinase C (PKC) activities were able to modulate Pgp MDR (Yu et al., 1991; Bates et al., 1992; Chambers et al., 1992) . Stimulation of Pgp phosphorylation by PKC activators PMA (TPA) was correlated with a decrease of drug accumulation (Bates et al., 1992; Chambers et al., 1992; Fine et al., 1988) , while inhibition of Pgp phosphorylation by staurosporine, a protein kinase inhibitor, caused an increase of drug accumulation by inhibition of the drug efflux (Chambers et al., 1992; Ma et al., 1991) . Furthermore, in Pgp expressing BC-19 cells transfected with PKCa, Pgp was more phosphorylated and this resulted in more resistant cells with a further decreased vinblastine accumulation compared to the cells without PKCa transfection (Yu et al., 1991) . Moreover, PKC seemed to be involved in drug resistance independent of Pgp, since exposure of drug-sensitive cell lines to phorbol ester induced a drug-resistant phenotype (Takeda et al., 1991; Fine et al., 1988) . Interestingly, in one such a cell line selected for resistance to TPA (K562/TPA) genistein, a tyrosine kinase inhibitor, was able to alter the subcellular doxorubicin distribution (Takeda et al., 1992 As measured by trypan blue exclusion, the cells remained viable during the drug accumulation studies with genistein and staurosporine.
Cells
The human non-small cell lung carincoma cell line SW-1573 and the doxorubicin resistant sublines SW-1573/2R120 (2R120, non-Pgp MDR) and SW-1573/2R160 (2R160, Pgp MDR) have been described elsewhere . The human breast cancer cell line MCF7 and the non-Pgp MCF7/Mitox and the Pgp MCF7/DOX sublines were obtained from Dr W. Dalton (Taylor et al., 1991) . The human epidermoid carcinoma cell line KB3-1 and its Pgp MDR subline KB8-5 were obtained from Dr I. Roninson (KB3-1) or through ATCC, Rockville, MD (KB8-5). The human fibrosarcoma cell line HT1080 and its doxorubicinselected non-Pgp MDR subline HT1O8O/DR4 were provided by Dr M Slovak (Slovak et al., 1988) . All cell lines mentioned were cultured in monolayer in Nunc flasks (Roskilde, Denmark) in Dulbecco's modified Eagle's medium (DMEM, Flow, Irvine, UK) supplemented with 7.5% heat-inactivated foetal calf serum (GIBCO, Paisley, UK). The human small cell lung carcinoma cell line GLC4 and its doxorubicinresistant subline GLC4/ADR have been characterised before (Zijlstra et al., 1987; De Jong et al., 1990) . The human acute myeloblastic leukaemia cell line HL60 and its non-Pgp MDR subline HL60/ADR were obtained from Dr M. Center (McGrath et al., 1989) . The GLC4 and HL60 cell lines were grown as floating cells in RPMI medium (Flow Labs., Irvine, Scotland) with 10% foetal calf serum. The resistant cells were cultured in the presence of selecting drug until 2-10 days before experiments (except HL6O/ADR cells which were cultured without drug). All cell lines were free from mycoplasma as tested regularly with the Mycoplasma T.C. rapid detection system with a 3H-labelled DNA probe from Gen-Probe Inc. (San Diego, CA).
For growth inhibition experiments, cells were plated in 96-well plate (2000 cells/well) and after 24h exposed continuously with varying concentrations genistein. Cells were then grown for 5 days. The cells were stained with MTT, and the absorption was measured as previously reported ).
Phosphorylation of P-glycoprotein Cells were incubated in 6-well plates with 0.05-0.2mCi of [32P]orthophosphoric acid in 1 ml of phosphate-free growth medium with 2% foetal calf serum for 4 h. PMA or staurosporine were added during the last 30 min of incubation. Cells were then washed with ice-cold PBS, harvested by scraping and homogenised in phosphate buffer containing 1% NP-40, 10 mM NaF and 1 mM PMSF. P-glycoprotein was immunoprecipitated with monoclonal antibody C-219 (Centocor, Inc., Malvern, PA) as described (Scheper et al., 1993) .
Cellular drug accumulation
The steady-state cellular accumulation of [3H]daunorubicin and [3H]VP-16 was measured as described previously (Broxterman et al., 1988) . Briefly, cells were incubated in growth medium without sodium bicarbonate, but with 10% foetal calf serum. DNAseI (0.025%) was included to prevent DNR accumulation in any non-viable cells. The assay was initiated by addition of the radiolabelled drug in the presence of either the modulator of interest or the solvent alone. After 60 min, the cells were rapidly washed twice with ice-cold phosphate buffered saline.
For drug efflux, cells were incubated for 60 min with the radiolabelled drug. After one wash with ice-cold phosphate buffered saline, cells were resuspended in pre-warmed medium. At the indicated time points the efflux was stopped by another wash with ice-cold phosphate buffered saline. Radioactivity was determined by liquid scintillation counting.
Intracellular distribution of doxorubicin Measurement of subcellular doxorubicin distribution was performed as described previously (Schuurhuis et al., 1989 (Schuurhuis et al., , 1991 . Cells were allowed to adhere on tissue culture petri dishes (Costar, Cambridge, MA) for 24 h. Floating cells were allowed to adhere on Falcon dishes for 15 min in serum free medium at 4°C. Cells were incubated in growth medium for 1.5 h with 8 or 32 tiM doxorubicin at 37°C. After a rapid wash with phosphate buffer saline, 10-30 cells were recorded for each treatment using laser scan microscopy. Fluorescence of doxorubicin in the nucleus and the fluorescence in the cytoplasm were quantifed using digital image analysis as described (Schuurhuis et al., 1989; De Lange et al., 1992) .
Results
Effects of PMA and staurosporine on DNR accumulation in
MDR cells
The effects of the protein kinase modulators PMA and staurosporine on DNR accumulation were examined in the non-Pgp MDR lung carcinoma cell lines, 2R120 and GLC4/ ADR, and compared with the Pgp expressing subline 2R160. (Figure lb) . Blocking active drug transport by addition of 10 mm sodium azide and 25 mg ml-l deoxyglucose (5-fold excess glucose) also resulted in a decrease of Pgp phosphorylation. Thus, the effects of modulation of PKC activity in the Pgp expressing 2R160 MDR subline were consistent with other reports (Chambers et al., 1992; Ma et al., 1991) . Therefore, we could compare the effects of PMA and staurosporine on the DNR accumulation in the non-Pgp MDR cells with the 2R160 cells.
In Figure 2 We have shown previously that the accumulation of DNR in GLC4/ADR cells is decreased merely due to an enhanced energy-dependent efflux (Versantvoort et al., 1992b ). Therefore we now studied the effects of genistein on drug efflux. The enhanced efflux of DNR from the GLC4/ADR cells was inhibited partly with 200 JM genistein and completely with 50011M genistein (Figure 4) , which is in accordance with the effects on DNR accumulation (Figure 3) . Genistein had no effect on the efflux of DNR from the parental GLC4 cells (Figure 4) , showing that the passive transport of DNR is not affected by 200 AM genistein.
In order to determine the specificity of the genistein effects for non-Pgp MDR cells, we examined the effects of genistein on DNR accumulation in several Pgp (2R160, and MCF7/DOX40) and non-Pgp (GLC4/ADR, 2R120, HT1080/ DR4, MCF7/Mitox and HL60/ADR) MDR cells ( Figure 5 ). (Schuurhuis et al., 1989 (Schuurhuis et al., , 1991 Gervasoni et al., 1991) ; the ratio of nuclear to cytoplasmic doxorubicin fluorescence (N/C ratio) is lower in the resistant cells. We have shown previously that verapamil did not change the subcellular distribution of doxorubicin in non-Pgp MDR 2R120 cells in contrast to the increase of the N/C ratio's in the Pgp expressing SW-1573 sublines (Schuurhuis et al., 1991) . In order to know whether genistein was able to reverse not only the decreased drug accumulation in non-Pgp MDR cells but could also alter the drug distribution, we examined the effects of genistein on the subcellular distribution of doxorubicin.
In Table II the cellular doxorubicin distribution is reflected as the N/C ratio. Firstly, the N/C ratio is lower in the MDR cell lines compared to their parental cell lines (shown in Figure 6a and 6b). Secondly, in the non-Pgp MDR GLC4/ ADR cells, the N/C ratio increased in response to exposure to genistein illustrated in Figure 6b and c. Thirty-twoylM verapamil also increased the N/C ratio in the GLC4/ADR cells (Figure 6d ). In the non-Pgp MDR 2R120 cells the N/C ratio increased to a small extent in response to exposure to genistein or verapamil. In these cells genistein increased the N/C ratio in all the five independent experiments. The N/C ratio increased in the Pgp MDR 2R160 cells only when using verapamil but not with genistein and in the parental cell lines the N/C ratio was not affected by either verapamil or genistein.
Cytoxocity ofgenistein
We have shown that genistein is able to reverse the decreased drug accumulation in non-Pgp MDR tumour cells. In order to know whether genistein could be used as a resistance modifier, the cytotoxicity of genistein was measured. In Table  III it is shown that genistein is about equally toxic to the parental and the resistant cells. However, the concentrations of genistein used in the drug accumulation studies were too toxic to use for continuous exposure in drug cytotoxicity experiments.
Comparative effects ofgenistein and structurally related compounds on the DNR accumulation in GLC4 cells In order to gain insight into the mechanism of action of genistein on drug accumulation, effects of other isoflavonoids and flavonoids on DNR accumulation were examined (Table   c80   410 . Figure 6 Changes in intracellular doxorubicin distribution due to exposure to genistein and verapamil. The procedure followed is described in 'Materials and methods'. GLC4: a, 1. IV). The structures of these compounds are depicted in Figure 7 . These compounds were less effective than genistein in inhibition of tyrosine kinases (Akiyama et al., 1987) .
The isoflavonoid biochanin A increased the DNR accumulation in the parent GLC4 as well as in the resistant GLC4/ADR cells; the increase was much more pronounced in the resistant cells than in the sensitive cells (12-fold vs 1.5-fold). The flavonoids apigenin and quercetin increased the DNR accumulation in the GLC4/ADR cells, while a small decrease was measured in the GLC4 cells. From the compounds tested, only biochanin A significantly enhanced the DNR accumulation in the Pgp MDR 2R160 cells (not shown).
It was checked whether the effects of the (iso)flavonoids on the parental GLC4 and GLC4/ADR cells were due to changes in intracellular pH, since DNR accumulation is dependent on the pH (Skovsgaard & Nissen, 1982; Versantvoort et al., 1992a,b) . Therefore, intracellular pH was measured using the pH sensitive, fluorescent dye BCECF (Versantvoort et al., 1992b) . Genistein had no effect on the intracellular pH in the parental and resistant GLC4 cells. Biochanin A, however, lowered the intracellular pH 0.25-0.3 in both the parent and resistant GLC4 cells. A lower intracellular pH will result in a higher intracellular DNR accumulation, since only the neutral form of DNR is passively transported over the plasma membrane. Thus the lowered intracellular pH could explain the increase of DNR accumulation by biochanin A in the GLC4 cells, and in part the large increase of DNR accumulation in the GLC4/ADR cells as calculated according to the Henderson-Hasselbach equation (Skovsgaard & Nissen, 1982) . Changes in intracellular pH due to exposure to apigenin and quercetin could not be determined reliably, because of interference of these compounds with the fluorescence of BCECF.
Discussion
Overexpression of Pgp has been well established as the cause of the MDR phenotype in many in vitro selected drug resistant cell lines. In many human cancers Pgp/mdrl has been demonstrated using monoclonal antibodies or gene probes (Chan et al., 1990; Noonan et al., 1990; Bourhis et al., 1989) . Only in a few studies, however, the level of Pgp expression in human tumours was correlated with their resistant phenotype. Nooter et al. (1990) , showed that the mdrl mRNA expression correlated with a cyclosporin-A-induced increase in cellular DNR accumulation in fresh human leukemia cells. Interestingly, indications for the presence of the other drug transporters were provided since in some samples without detectable mdrl expression a cyclosporin-Ainduced increase in cellular DNR accumulation was measured.
However, agents affecting the activity of Pgp may or may not affect other MDR mechanisms (Schuurhuis et al., 1991; Cole et al., 1989; Zijlstra et al., 1987 (Marquardt et al., 1990; Barrand et al., 1993; Versantvoort et al., 1992c) . Preliminary results with antibodies derived against synthetic peptides encoded by the MRP gene, revealed that the 190 kD protein is the product of the MRP gene (Cole, 1993) . Another protein of 110 kD is also overexpressed in most but not all of the non-Pgp MDR cell lines (Scheper et al., 1993) . In normal tissue this 110 kD protein is like Pgp highly expressed in tissue with secretory-excretory functions (Scheper et al., 1993) . Further investigation of these proteins will reveal their involvement in drug transport in MDR cells not mediated by Pgp. Genistein is potent and specific inhibitor of tyrosine kinase activity, as measured by inhibition of autophosphorylation of EGF receptor in membranes of A431 cells (Akiyama et al., 1987) . Furthermore genistein (<25 JLM) has been shown to affect cell proliferation and differentiation either via its ability to interact with protein tyrosine kinases, phosphatidylinositol kinases or via inhibition of DNA topoisomerase II (Dean et al., 1989; Honma et al., 1992; Yoneda et al., 1991) . A common sequence at or near the ATP-binding site may account for the inhibition of this diverse group of enzymes (Markovits et al., 1989; Akiyama et al., 1987) . Among the flavonoids and isoflavonoids tested here, quercetin is known to inhibit not only tyrosine kinases but also PKC, phosphorylase kinase and 5'-nucleotidase, whereas apigenin and biochanin A exhibit only low activity for inhibition of EGF receptor phosphorylation (Akiyama et al., 1987) . These analogues were shown to be inactive in inhibition of DNA topoisomerase II activity (Markovits et al., 1989) . In contrast with those effects specific for genistein, also quercetin, apigenin and biochanin A caused an increase in DNR accumulation in the non-Pgp MDR GLC4/ADR cells (Table  IV) . This suggests that other mechanisms than inhibition of a tyrosine kinase might affect the drug transport in non-Pgp MDR cells, although a role for a tyrosine kinase with a different sensitivity profile and low affinity for genistein cannot be excluded.
One might suggest that genistein binds directly to the drug transporter(s) in the non-Pgp MDR cells. The non-Pgp MDR cells, however, lacked cross-resistance to genistein (Table III) , suggesting that genistein is not effluxed itself (also suggesting that inhibition of topoisomerase II was not the major determinant of cell-kill in these cells, Markovits et al., 1989) . However, lack of cross-resistance in Pgp MDR cells to resistance modifier verapamil had been demonstrated , although verapamil is thought to modulate the drug transport in Pgp MDR cells by binding to and by being itself pumped out of the cells by Pgp (Yusa & Tsuruo, 1989; Qian & Beck, 1990) . Therefore, further studies with genistein should be done to reveal whether such a mechanism is the basis of the effect of genistein on drug transport in non-Pgp MDR cells. Since the cytotoxic effects of genistein might be due to the inhibition of protein tyrosine kinases, it is worthwhile to search for less toxic analogues, which might be able to reverse the resistance in non-Pgp MDR tumour cells. 
